Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
What Is Wegovy prior authorization?
Wegovy prior authorization is the payer review a plan requires before it will cover semaglutide 2.4mg. It confirms the patient meets eligibility criteria (BMI 30+, or BMI 27+ with a documented weight-related comorbidity) and that the plan actually covers anti-obesity medications. The plan checks BMI with a measurement date, comorbidity ICD-10 codes, documented lifestyle modification, and any step therapy or prior medication trials before approving the prescription.
Why Is Wegovy Eligibility and Prior Authorization Important?
Wegovy (semaglutide 2.4mg) demonstrated 15% average weight loss over 68 weeks in clinical trials, making it one of the most effective anti-obesity medications available. But clinical effectiveness does not guarantee insurance coverage, and coverage does not guarantee approval without proper documentation.
PA matters across three dimensions. For patient access, Wegovy costs approximately $1,349 per month without insurance coverage, making it inaccessible for most patients without a successful PA. For practice revenue, the CAQH Index estimates the PA system costs providers $35 billion annually in administrative burden, and GLP-1 PAs are among the most documentation-intensive. For clinical outcomes, the AMA reports 93% of physicians see care delays from PA, and Wegovy specifically requires 16 weeks of dose titration before reaching the therapeutic dose. Any interruption during titration forces the patient to restart from the beginning, causing rebound weight gain, patient frustration, and clinical dropout. A clean first PA submission is the single most effective way to prevent these problems and keep patients on their treatment trajectory.
Who Qualifies for Wegovy? FDA Eligibility Criteria
The FDA prescribing information defines the eligible patient populations. Payers generally follow these criteria but may add stricter requirements.
Adults: BMI of 30 or greater qualifies without additional conditions. BMI of 27 to 29.9 qualifies when accompanied by at least one weight-related comorbidity: type 2 diabetes (T2DM), hypertension, dyslipidemia, obstructive sleep apnea (OSA), cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), or polycystic ovary syndrome (PCOS). Document the specific comorbidity with the corresponding ICD-10 code. An undocumented comorbidity does not count for PA purposes.
Adolescents (12+): BMI at or above the 95th percentile for age and sex. Pediatric coverage varies significantly by payer, and many Medicaid programs do not cover Wegovy for patients under 18.
Cardiovascular indication (approved March 2024): Adults with established cardiovascular disease and obesity or overweight, prescribed to reduce the risk of cardiovascular death, heart attack, and stroke. This indication is important because it provides a coverage pathway for Medicare Part D patients who cannot access Wegovy for weight loss alone until the GLP-1 Bridge begins in July 2026.
Oral Wegovy (approved December 2025): The oral formulation carries the same weight management indications as the injectable. Payer coverage and PA requirements may differ between oral and injectable formulations. Check formulary status for each formulation separately.
All uses require concurrent reduced-calorie diet and increased physical activity. Most payers verify documented lifestyle modification, meaning your clinical notes must show that dietary counseling and exercise prescription are part of the treatment plan. Source: FDA prescribing information.
What Information Is Verified During PA?
The PA review process examines both clinical and administrative information. Understanding what the payer checks helps you submit a complete package on the first attempt.
Clinical verification: BMI documented with a specific date of measurement (undated BMI is a top denial trigger). Comorbidity documentation with ICD-10 codes for patients with BMI 27-29.9 (the comorbidity must be actively coded in the chart, not just mentioned in a note). Lifestyle modification history covering 3-6 months depending on the payer, with specific dates and interventions documented. Prior medication trials if step therapy applies, including drug name, dose, duration, and reason for discontinuation. Prescriber qualifications, as some plans require a specialist prescriber for initial approval.
Administrative verification: Active coverage confirmed through the pharmacy benefit. Plan-level drug coverage verified, because the employer may exclude anti-obesity medications even when the drug appears on the insurer’s standard formulary. Formulary status and tier placement for the specific formulation prescribed. Quantity limits, which are typically one pen per 28 days for each titration step and the maintenance dose.
Save 40-70% with dedicated PA specialists
Book a 15-minute call. We will map your current prior authorization workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
Step-by-Step Wegovy PA Submission Process
Step 1: Confirm plan-level coverage. Call pharmacy benefits number. Verify AOM coverage, formulary status, step therapy. If plan excludes weight loss drugs entirely, no PA will be approved.
Step 2: Gather documentation: BMI with date, comorbidities with ICD-10, lifestyle modification records (3-6 months), prior medication trials, LMN, prescriber NPI.
Step 3: Complete payer-specific PA form via portal, CoverMyMeds, or Surescripts. Attach all documentation with initial submission. NovoCare provides PA tools at novomedlink.com.
Step 4: Submit and track. CMS-0057-F: 7-day standard, 72-hour urgent. Monitor portal daily. Respond to additional info requests within 24 hours.
Step 5: Document approval: auth number, dates, dose, quantity, reauth conditions. Set reminder 30 days before expiration.
Step 6: Handle reauthorization. Most payers require 5%+ weight loss from baseline. Track weight at every visit.
NovoCare Savings Card reduces copay to $25/month for eligible commercially insured patients.
Wegovy PA Requirements by Major Payer
Payer requirements vary significantly. Knowing the specific criteria before submission prevents denials and saves staff time.
CVS Caremark: Designated Wegovy as the preferred GLP-1 for weight management since July 2025, dropping Zepbound from preferred status. Standard criteria: BMI 30+ or 27+ with documented comorbidity. Reauthorization requires 5%+ weight loss from baseline within the initial approval period. CVS Caremark covers the largest commercial prescription volume in the U.S., so this formulary position affects millions of patients.
UnitedHealthcare: Coverage varies dramatically by plan document. Some employer plans set the BMI threshold at 40+, well above the FDA-approved 30. Other UHC plans follow FDA criteria at BMI 30 or 27 with comorbidity. There is no standard UHC Wegovy policy. You must check the specific plan document for each patient, which requires calling the pharmacy benefits number.
BCBS: Most BCBS affiliates require BMI 30+ or 27+ with comorbidity, plus 3 or more months of documented lifestyle modification. However, BCBS coverage varies by affiliate. BCBS Michigan ended all GLP-1 weight loss coverage in January 2025. Anthem BCBS in Ohio has among the most restrictive criteria. Check the specific affiliate’s current policy before submitting.
Aetna: Requires BMI 30+ or 27+ with comorbidity plus 6 months of documented lifestyle modification, one of the longest lifestyle documentation requirements among major payers. Step therapy may apply depending on the specific plan. The 6-month requirement means clinical staff must begin documenting lifestyle interventions from the patient’s first visit.
Cigna: Covers GLP-1s for weight management with PA on many employer-sponsored plans. Step therapy requirements vary by plan and may include a trial of phentermine-topiramate or orlistat before Wegovy approval.
Medicare Part D (through June 2026): No coverage for Wegovy for weight loss. The only currently covered indication is cardiovascular risk reduction in patients with established CVD and obesity. Starting July 2026, the Medicare GLP-1 Bridge program covers Wegovy at $50 per month for eligible Part D beneficiaries with BMI 35+ or BMI 27+ with clinical criteria.
Common Denial Reasons and How to Appeal
Plan excludes AOMs. No appeal overturns this. Confirm plan-level coverage before submitting.
Insufficient lifestyle documentation. Payer requires 3-6 months. Start documenting from first visit. Include dated notes, referrals, patient activities.
Step therapy not met. Document clinical contraindication to required alternative (cardiac risk with phentermine, GI intolerance with orlistat). Request medical exception.
BMI below plan threshold. Confirm threshold before submitting. Request peer-to-peer if BMI 32 with comorbidities vs. plan threshold of 40.
Incomplete documentation. Use a PA checklist for every submission. Missing even one required element, such as a dated BMI or a specific comorbidity ICD-10 code, triggers an information request that adds 7-14 days to the approval timeline.
The appeal process: Most payers allow 180 days for appeal filing. Over 80% of MA PA appeals overturned but only 1 in 10 patients appeal (KFF/OIG 2023). 44% of commercial appeals successful. Always appeal before accepting a denial as final.
Wegovy Coverage by State: Florida, Texas, and Ohio
Florida: Medicaid does not cover Wegovy or any GLP-1 for weight loss. Access limited to T2DM diagnoses. Florida Blue covers Wegovy on some employer-sponsored plans with PA. CMS BALANCE Model participation could change Medicaid access.
Texas: Among 22 states with partial Medicaid GLP-1 coverage. Wegovy may be covered through MCOs (Superior, Molina, UHC Community Plan, Amerigroup). Each MCO has own portal and formulary. Texas commercial market is heavily self-funded with many employers excluding weight loss drugs.
Ohio: Medicaid does not cover GLP-1s for weight loss. One of 14 states with no obesity GLP-1 Medicaid coverage. Commercial varies by employer plan. Monitor CMS BALANCE Model participation.
For all three states: confirm coverage at the plan level, not state level. A state-level Medicaid exclusion is final, but commercial coverage varies by employer plan document, which means the same insurer may cover Wegovy for one patient and exclude it for another based entirely on who their employer is and what benefit package was purchased.
How Staffingly Handles Wegovy Prior Authorization
Staffingly Wegovy prior authorization specialists handle: plan-level coverage confirmation, full documentation gathering, payer-specific form completion, real-time tracking with daily updates, denial management and appeal coordination, and reauthorization tracking with 30-day advance reminders.
The patient financial counseling component of Wegovy PA should not be overlooked. Even with PA approval, patient cost sharing for GLP-1 medications can exceed 500 dollars per month on many commercial plans.
800+ providers. 99.2% clean claim rate. $399/week (volume discounts to $299/week), 70% savings vs. in-house. 48-72 hour go-live. 50+ EHR platforms. SOC 2, HITRUST, ISO 27001, HIPAA compliant.
What People Are Asking (FAQs)
What BMI do I need to qualify for Wegovy? BMI 30+ qualifies alone. BMI 27+ qualifies with a weight-related comorbidity. Adolescents 12+ qualify at 95th percentile. Payers may set higher thresholds. Confirm plan criteria before submitting. Source: FDA prescribing information.
Does Wegovy always require PA? In most cases, yes. The administrative burden is significant given the growing patient population seeking GLP-1 prescriptions. Over 88% of covered patients face PA or step therapy. Some plans exclude AOMs entirely at the plan level, making PA impossible regardless of formulary listing.
How long does Wegovy PA take? Turnaround depends on the payer and the completeness of the initial submission. Typically 1-7 business days. CMS-0057-F: 7-day standard, 72-hour urgent. Incomplete submissions extend by weeks.
What happens if my Wegovy PA is denied? File internal appeal, request peer-to-peer, or submit additional documentation. Over 80% of MA appeals overturned (KFF/OIG 2023). 44% of commercial appeals successful. Most payers allow 180 days.
Will Medicare cover Wegovy for weight loss in 2026? Yes, starting July 2026. GLP-1 Bridge: $50/month for eligible Part D beneficiaries. Bridge runs July-December 2026. BALANCE Model covers from January 2027.
Does Medicaid cover Wegovy? Only in some states. 13 programs cover GLP-1s for obesity. Texas partial via MCOs. FL and OH do not. BALANCE Model may expand coverage May 2026.
How much does Wegovy cost with insurance? 90% of commercially insured patients pay $0-$25/month with NovoCare Savings Card plus coverage. Without savings card: $25-$150/month. Without insurance: ~$1,349/month (GoodRx 2026).
When practices handle prior authorization internally, the hidden costs add up quickly. Staff overtime, claim resubmissions, delayed patient care, and provider frustration all contribute to a problem that grows worse as payer requirements tighten. Outsourcing PA to a dedicated team with payer-specific expertise removes this burden. Staffingly’s PA specialists work across 50+ EHR platforms and handle the full PA lifecycle from submission to appeal, going live within 48-72 hours at $399/week (volume discounts to $299/week).
What Did We Learn?
Wegovy PA requires documentation discipline, payer-specific knowledge, and proactive tracking. The process is not a single submission. It is a multi-step workflow that begins with plan-level coverage confirmation and extends through reauthorization, where most payers require 5%+ weight loss from baseline to keep the patient on therapy.
